Cooper Companies (NYSE:COO) had its price objective increased by investment analysts at BMO Capital Markets from $294.00 to $306.00 in a research note issued on Friday, The Fly reports. The brokerage currently has an “outperform” rating on the medical device company’s stock. BMO Capital Markets’ price objective indicates a potential upside of 25.92% from the stock’s current price.
A number of other analysts have also recently weighed in on COO. Zacks Investment Research cut Cooper Companies from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Oppenheimer set a $270.00 price target on Cooper Companies and gave the stock a “hold” rating in a research report on Friday, August 31st. Raymond James increased their price target on Cooper Companies from $270.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, September 21st. ValuEngine upgraded Cooper Companies from a “hold” rating to a “buy” rating in a research report on Thursday, September 27th. Finally, Wells Fargo & Co increased their price target on Cooper Companies from $290.00 to $295.00 and gave the stock an “outperform” rating in a research report on Monday, November 12th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $284.50.
Shares of NYSE COO opened at $243.01 on Friday. Cooper Companies has a 52-week low of $216.47 and a 52-week high of $283.18. The company has a market cap of $13.61 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 2.13 and a beta of 0.77. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 2.58.
Cooper Companies (NYSE:COO) last announced its quarterly earnings data on Thursday, December 6th. The medical device company reported $2.87 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.96 by ($0.09). The firm had revenue of $651.50 million for the quarter, compared to analyst estimates of $645.25 million. Cooper Companies had a net margin of 5.52% and a return on equity of 17.86%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.65 EPS. As a group, equities research analysts predict that Cooper Companies will post 12.1 EPS for the current fiscal year.
In related news, COO Daniel G. Mcbride sold 10,310 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $264.44, for a total value of $2,726,376.40. Following the sale, the chief operating officer now directly owns 38,705 shares in the company, valued at approximately $10,235,150.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Randal Golden sold 1,731 shares of the firm’s stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $275.86, for a total value of $477,513.66. Following the completion of the sale, the vice president now owns 1,154 shares in the company, valued at $318,342.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 20,691 shares of company stock worth $5,527,869. 1.60% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of COO. Findlay Park Partners LLP increased its position in Cooper Companies by 225.0% in the 3rd quarter. Findlay Park Partners LLP now owns 738,824 shares of the medical device company’s stock valued at $204,765,000 after acquiring an additional 511,518 shares during the period. Janus Henderson Group PLC increased its position in Cooper Companies by 23.8% in the 2nd quarter. Janus Henderson Group PLC now owns 2,618,690 shares of the medical device company’s stock valued at $616,595,000 after acquiring an additional 502,783 shares during the period. Putnam Investments LLC increased its position in Cooper Companies by 228.5% in the 3rd quarter. Putnam Investments LLC now owns 622,865 shares of the medical device company’s stock valued at $172,627,000 after acquiring an additional 433,242 shares during the period. Morgan Stanley boosted its stake in Cooper Companies by 734.7% during the 3rd quarter. Morgan Stanley now owns 177,658 shares of the medical device company’s stock valued at $49,238,000 after purchasing an additional 156,373 shares in the last quarter. Finally, Marshall Wace North America L.P. boosted its stake in Cooper Companies by 875.3% during the 3rd quarter. Marshall Wace North America L.P. now owns 144,900 shares of the medical device company’s stock valued at $40,159,000 after purchasing an additional 130,043 shares in the last quarter.
Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Read More: Trading Strategy Examples and Plans
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.